Heron Therapeutics, Inc. (HRTX)
HRTX Stock Price Chart
Explore Heron Therapeutics, Inc. interactive price chart. Choose custom timeframes to analyze HRTX price movements and trends.
HRTX Company Profile
Discover essential business fundamentals and corporate details for Heron Therapeutics, Inc. (HRTX) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
26 Aug 1987
Employees
122.00
Website
https://www.herontx.comCEO
Craig Alexander Collard
Description
Heron Therapeutics, Inc. is a biotechnology firm dedicated to creating innovative therapies for critical patient requirements. The company leverages its proprietary Biochronomer drug delivery platform, an advanced system that enables the controlled release of various short-acting pharmacological agents. This technology ensures therapeutic concentrations are maintained for periods ranging from days to weeks following just a single administration. Among its commercialized products is SUSTOL (granisetron), an extended-release injectable designed to prevent both immediate and delayed nausea and vomiting triggered by moderately emetogenic chemotherapy, or specific anthracycline and cyclophosphamide combination therapies. Additionally, Heron markets CINVANTI, an intravenous formulation of aprepitant. CINVANTI, which acts as a substance P/neurokinin-1 receptor antagonist, is indicated for the prevention of acute and delayed chemotherapy-induced nausea and vomiting in patients undergoing highly or moderately emetogenic cancer chemotherapy. The company's development pipeline includes ZYNRELEF, an innovative dual-acting local anesthetic that combines bupivacaine, a local anesthetic, with a low dose of the nonsteroidal anti-inflammatory drug (NSAID) meloxicam in a single fixed-dose formulation. Also in development is HTX-019, an experimental therapy aimed at preventing postoperative nausea and vomiting (PONV). Furthermore, HTX-034 is being advanced for postoperative pain management and is currently undergoing Phase Ib/II clinical trials, notably in patients recovering from bunionectomy procedures. Originally established in 1983 as A.P. Pharma, Inc., the company adopted its current name, Heron Therapeutics, Inc., in January 2014. Its corporate headquarters are situated in San Diego, California.
HRTX Financial Timeline
Browse a chronological timeline of Heron Therapeutics, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 14 Aug 2026
EPS estimate is -$0.02, while revenue estimate is $42.19m.
Earnings released on 11 May 2026
EPS came in at -$0.04 falling short of the estimated -$0.03 by -33.33%, while revenue for the quarter reached $34.71m , missing expectations by -5.46%.
Earnings released on 26 Feb 2026
EPS came in at -$0.02 surpassing the estimated -$0.03 by +33.33%, while revenue for the quarter reached $40.59m , beating expectations by +1.81%.
Earnings released on 4 Nov 2025
EPS came in at -$0.05 falling short of the estimated -$0.01 by -275.09%, while revenue for the quarter reached $38.21m , missing expectations by -2.10%.
Earnings released on 8 Aug 2025
EPS came in at -$0.02 falling short of the estimated -$0.01 by -100.00%, while revenue for the quarter reached $37.20m , missing expectations by -4.75%.
Earnings released on 6 May 2025
EPS came in at $0.01 surpassing the estimated -$0.01 by +200.00%, while revenue for the quarter reached $38.90m , beating expectations by +1.71%.
Earnings released on 27 Feb 2025
EPS came in at $0.02 surpassing the estimated -$0.03 by +166.67%, while revenue for the quarter reached $40.78m , beating expectations by +11.20%.
Earnings released on 12 Nov 2024
EPS came in at -$0.03 falling short of the estimated -$0.03 by -9.09%, while revenue for the quarter reached $42.27m , beating expectations by +13.12%.
Earnings released on 6 Aug 2024
EPS came in at -$0.06 falling short of the estimated -$0.04 by -50.00%, while revenue for the quarter reached $36.02m , missing expectations by -1.63%.
Earnings released on 7 May 2024
EPS came in at -$0.02 surpassing the estimated -$0.08 by +75.00%, while revenue for the quarter reached $34.67m , missing expectations by -3.40%.
Earnings released on 12 Mar 2024
EPS came in at -$0.07 surpassing the estimated -$0.15 by +53.33%, while revenue for the quarter reached $34.23m , beating expectations by +10.54%.
Earnings released on 14 Nov 2023
EPS came in at -$0.17 surpassing the estimated -$0.31 by +45.16%, while revenue for the quarter reached $31.43m , beating expectations by +1.60%.
Earnings released on 14 Aug 2023
EPS came in at -$0.35 falling short of the estimated -$0.23 by -52.17%, while revenue for the quarter reached $31.76m , beating expectations by +0.20%.
Earnings released on 11 May 2023
EPS came in at -$0.27 falling short of the estimated -$0.17 by -58.82%, while revenue for the quarter reached $29.62m , missing expectations by -0.25%.
Earnings released on 23 Mar 2023
EPS came in at -$0.17 surpassing the estimated -$0.25 by +32.00%, while revenue for the quarter reached $30.03m , beating expectations by +11.63%.
Earnings released on 8 Nov 2022
EPS came in at -$0.38 surpassing the estimated -$0.39 by +2.56%, while revenue for the quarter reached $26.56m , missing expectations by -1.49%.
Earnings released on 9 Aug 2022
EPS came in at -$0.55 falling short of the estimated -$0.50 by -10.00%, while revenue for the quarter reached $27.63m , beating expectations by +12.54%.
Earnings released on 9 May 2022
EPS came in at -$0.63 falling short of the estimated -$0.45 by -40.00%, while revenue for the quarter reached $23.46m , beating expectations by +3.76%.
Earnings released on 28 Feb 2022
EPS came in at -$0.54 surpassing the estimated -$0.59 by +8.47%, while revenue for the quarter reached $20.66m , missing expectations by -19.86%.
Earnings released on 3 Nov 2021
EPS came in at -$0.51 surpassing the estimated -$0.60 by +15.00%, while revenue for the quarter reached $23.23m , missing expectations by -8.94%.
Earnings released on 9 Aug 2021
EPS came in at -$0.62 falling short of the estimated -$0.59 by -5.08%, while revenue for the quarter reached $22.44m , meeting expectations.
HRTX Stock Performance
Access detailed HRTX performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
